Ceylon Serenity

Investor overview

A healthcare export institution, structured for capital protection.

Ceylon Serenity Recovery earns hard-currency revenue from European clients while operating on a Sri Lankan cost base, under BOI incentives that guarantee full profit repatriation.

Investment thesis

Why this institution, why Sri Lanka, why now.

01

Hard-currency revenue

Every programme is priced and billed in USD or EUR, insulating returns from local currency volatility.

02

Structural cost arbitrage

Roughly 50% below Swiss and UK equivalents, while retaining premium pricing and margin.

03

Regulatory barrier to entry

Dual NDDCB and PHSRC licensing, SLMC-registered clinicians and a JCI pathway form a durable moat.

04

Sovereign incentives

BOI Wellness Tourism status: 5–12 year tax holiday, duty-free imports, 100% foreign ownership and repatriation.

Financial summary

Fifteen-villa resort targets.

All client services priced and billed in USD / EUR.

Total capitalisation (CAPEX)

$4.9M – $8.4M

Year 3 gross revenue

~$5.45M

Stabilised occupancy

65%

Projected gross margin

21% – 33%

Estimated break-even

~3 years

Projected ROI by Year 5

15% – 20%

Capital deployment

  • Beachfront land acquisition or long-term lease (up to 99 years)
  • Luxury villa construction and clinical fit-out
  • Advanced medical and Ayurvedic treatment infrastructure
  • Initial 12-month working capital

Revenue sensitivity

Explore the stabilised revenue model.

Adjust occupancy and the blended 28-day programme fee to see how annual gross revenue responds against the Year 3 plan.

Admissions per year

127

Occupied villa-nights

3,559

Gross annual revenue

$5.44M

vs. Year 3 plan

-0.0%

Gross profit at the projected 21% – 33% margin: $1.14M – $1.8M

Pre-development seed round

$50,000 – $150,000

Raised through two investor-protective structures, with capital released against defined milestones from escrow managed by Tier-1 legal counsel.

Option A — Convertible Loan Note / SAFE

  • $1.5M – $2.0M valuation cap
  • 20% conversion discount
  • 6% – 8% annual interest (convertible note)
  • Converts at the Primary Institutional Capitalisation Round

Option B — Direct Seed Equity

  • 5.0% – 7.0% ordinary shares
  • Offshore holding company or BOI special purpose vehicle
  • Milestone-restricted escrow releases
  • Escrow managed by Tier-1 Sri Lankan legal counsel

Use of seed proceeds

  1. 1. Formal bankable feasibility study
  2. 2. Tier-1 corporate legal counsel and escrow structuring
  3. 3. Preliminary BOI filings and NDDCB / PHSRC submissions

Option A illustrator

How your note converts.

Model a convertible note or SAFE converting at the Primary Institutional Capitalisation Round. Conversion uses the lower of the valuation cap or a 20% discount to the round’s pre-money valuation.

Illustrative only and simplified: assumes a pre-money conversion and excludes option pools and dilution from new money in the institutional round. Note interest is modelled at 7% simple (term sheet range 6%–8%). Definitive terms are set out in the legal documentation.

Conversion valuation

$1.75M

Mechanism applied

Valuation cap

Amount converting

$50,000

Effective discount

71%

Indicative equity

2.78%

Value at round price

$168.06K

Five core de-risking milestones

Each stage removes a category of risk before the next tranche of capital.

  1. 1Completed

    Sovereign alignment

    Meeting held at the Prime Minister’s Office, Colombo. The PM Secretariat is facilitating inter-agency coordination across BOI, NDDCB, the Ministry of Health and SLTDA.

  2. 2In progress

    Tier-1 legal engagement & escrow

    Corporate counsel engaged to structure the investment vehicle and milestone-restricted escrow.

  3. 3Q4 2026

    Statutory licensing filings

    Formal applications to the NDDCB and PHSRC.

  4. 4Q1 2027

    BOI approval & tax holiday

    Formal BOI Board approval with up to a 12-year corporate tax holiday.

  5. 5Following BOI approval

    Primary institutional round

    Launch of the $4.9M – $8.4M primary capitalisation round.

21-month roadmap

From feasibility to first intake.

Regulatory frameworks

National Dangerous Drugs Control Board (NDDCB)

Drug Dependent Persons (Treatment and Rehabilitation) Act, No. 54 of 2007

Private Health Services Regulatory Council (PHSRC)

Private Medical Institutions (Registration) Act, No. 21 of 2006

Board of Investment of Sri Lanka (BOI)

Board of Investment of Sri Lanka Act (Wellness Tourism Route)

  1. Months 1–3

    Feasibility & corporate setup

    • Close pre-development seed capital
    • Finalise Sri Lankan corporate and holding structures
    • Submit BOI pre-approvals
    • Present preliminary concept to the NDDCB

  2. Months 4–6

    Licensing & property

    • Secure the 99-year beachfront lease under BOI
    • Finalise full NDDCB and PHSRC applications
    • Register the primary Medical Director with the SLMC

  3. Months 7–18

    Construction & clinical headhunting

    • Execute the luxury villa build-out
    • Import specialist medical equipment under BOI duty exemptions
    • Assemble the European Psychiatric Advisory Board via Harley Street and Central European search networks

  4. Months 19–21

    Pre-launch to first intake

    • Cross-train clinical teams with Ayurvedic practitioners
    • Activate the European PR and media launch
    • Secure first client bookings and commence operations

Request the seed memorandum

Qualified investors may request the full pre-development seed capital memorandum and term sheet. All enquiries are handled personally by the Founder.

Ashan Corea Alwis

Founder & Chief Executive Officer

ashancorea@ceylonserenityrecovery.com

Please do not include clinical or medical details in this form. A member of the clinical team will arrange a confidential conversation.

Nature of enquiry